Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03678116 · ClinicalTrials.gov registry record · NA

Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses

A NA study of Blood Pressure and Mood, sponsored by University of Mary Hardin-Baylor.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT03678116: Completed NA study of Blood Pressure and Mood, sponsored by University of Mary Hardin-Baylor.

NCT03678116 is a NA study of Blood Pressure and Mood that has completed, run by University of Mary Hardin-Baylor. The registered enrollment target is 14 participants, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03678116, a NA study of Blood Pressure and Mood, has completed, sponsored by University of Mary Hardin-Baylor.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This a randomized, double blind, placebo controlled, crossover design study which measures the effect of an available thermogenic dietary supplement on resting energy expenditure (REE), blood pressure and heart rate, and mood changes in moderate caffeine consumers. Participants will complete baseline measurements then ingest one of three pills. Once the pill is ingested, subjects will complete four REEs along with heart rate and blood pressure and appropriate questionnaires. Participants will return two more times, each after a one week washout period, and complete the same protocol with the remaining supplements.

Primary Outcome

The primary purpose of this investigation is to determine the effectiveness of commercially available thermogenic dietary supplement on changing caloric expenditure via resting energy expenditure (REE) in daily, but modest caffeine consumers. This will be accomplished by observing caloric expenditure over a four hour time period post ingestion of the supplement as compared to baseline caloric expenditure pre-supplementation.

Interventions

  • DRUG Sugar Pill (placebo)
  • DIETARY_SUPPLEMENT Caffeine (plus Teacrine and Cayenne)
  • DIETARY_SUPPLEMENT Caffeine (plus Teacrine)

Study Locations (1)

Texas

  • UMHB Human Performance Lab - Belton

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2018-07-23
Est. Completion 2018-10-31
Phase NA
University of Mary Hardin-Baylor

10 total trials

What the finished NCT03678116 record still lists

NCT03678116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (95% lower).

The record links to 4 conditions, with Blood Pressure appearing as the primary indexed condition, and to 3 interventions - of which Sugar Pill (placebo) is the first listed.

NCT03678116 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03678116 about?

NCT03678116 is a clinical study titled "Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses". This a randomized, double blind, placebo controlled, crossover design study which measures the effect of an available thermogenic dietary supplement on resting energy expenditure (REE), blood pressure and heart rate, and mood changes in moderate caffeine consumers. Participants will complete baselin...

What is the current status of trial NCT03678116?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-07-23. Estimated completion is 2018-10-31.

What conditions does trial NCT03678116 study?

This clinical trial studies the following conditions: Blood Pressure, Mood, Energy Metabolism, Heart Rate.

What interventions are being tested in trial NCT03678116?

The interventions under investigation include: Sugar Pill (placebo) (DRUG), Caffeine (plus Teacrine and Cayenne) (DIETARY_SUPPLEMENT), Caffeine (plus Teacrine) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03678116?

This trial is sponsored by University of Mary Hardin-Baylor, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03678116 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blood Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03678116's enrollment target sits among peer trials

14 95th of 101 higher than 7 of 101 other Blood Pressure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03678116, the US trial registry maintained by the National Library of Medicine. NCT03678116 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.